CRL as reported
Charles River Laboratories reported $4.00B of revenue over the trailing twelve months, −0.74% on the year before. 11 reported series are charted on this page, each one as filed.
$4.00B
Revenue, trailing twelve months · to Q2 2026 · −0.74% against the twelve months before
- Net Income
- −$238M
Net Income · +256% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $371M
Free Cash Flow · −36% year on year · trailing twelve months to Q2 2026
- Op Margin
- 2.2%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $4.00B | −0.74% | Q2 2026 |
| Net Income | −$238M | +256% | Q2 2026 |
| EPS | −$4.79 | +274% | Q2 2026 |
| Gross Margin | 37% | n/a | Q4 2020 · 22 quarters behind |
| Op Margin | 2.2% | n/a | Q2 2026 |
| Net Margin | −6.0% | n/a | Q2 2026 |
| ROE | −5.4% | n/a | Q2 2026 |
| ROA | −2.2% | n/a | Q2 2026 |
| ROIC | 1.2% | n/a | Q2 2026 |
| Free Cash Flow | $371M | −36% | Q2 2026 |
| P/E | 26.7 | n/a | Q3 2024 · 7 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Charles River Laboratories (CRL) - Revenue & ProfitRevenue & ProfitCharles River Laboratories (CRL)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #17 of 29 by Smart Score